MedPath

Circadian Rhythm in Anti-Epileptic Drugs

Conditions
epilepsy
10039911
Registration Number
NL-OMON33832
Lead Sponsor
Christelijke Vereniging voor de Verpleging van Lijders aan Epilepsie
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
20
Inclusion Criteria

Diagnosed epilepsy
Age: 18 to 65 years
Capable of understanding the study and giving informed consent
>= 2 and <= 30 seizures per month
A chronotype other than *Neither morning nor eveningtype* according to the morningness/eveningsness questionnaire

Exclusion Criteria

Anamnestic history of circadian rhythm disorders, such as shift work or transmeridian travelling in the past month and/ or during the study
Change of therapy (AED/ combination/ dosage/ frequency) two months prior to and during the study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Time to nth seizure after adjusting administration times</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Quality of Life (measured by the Qolie-31 (Quality of Life in Epilepsy, version<br /><br>1.0 in Dutch))<br /><br>Adverse Drug Reaction (measured by The Stepped Care Adverse Drug Reaction List<br /><br>(in Dutch, by Prof. Dr. Aldenkamp))</p><br>
© Copyright 2025. All Rights Reserved by MedPath